Literature DB >> 12748672

B-cell lymphoma developing in the donor 9 years after donor-origin acute myeloid leukemia post bone marrow transplantation.

B Bielorai1, H J Deeg, M Weintraub, Y Neumann, E Rosner, N Amariglio, G Rechavi, A Toren.   

Abstract

Donor-cell leukemia post bone marrow transplantation is a rare event. Most of the cases reported to date have developed in cells from an HLA-matched sibling, who had no evidence of malignant disease before or following the occurrence of donor-origin leukemia. We describe a 17-year-old female who developed B-cell lymphoma 9 years following the occurrence of donor-origin acute myeloid leukemia in her brother for whom she had donated marrow. Cytogenetic analysis of the tumor revealed multiple chromosomal aberrations. The donor was heterozygous for the Ashkenazi mutation of Bloom's syndrome, suggesting that donor-type leukemia could have resulted from genomic instability in the donor cells.

Entities:  

Mesh:

Year:  2003        PMID: 12748672     DOI: 10.1038/sj.bmt.1703953

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  Donor cell-derived hematological malignancy: a survey by the Japan Society for Hematopoietic Cell Transplantation.

Authors:  M Kato; T Yamashita; R Suzuki; K Matsumoto; H Nishimori; S Takahashi; K Iwato; C Nakaseko; T Kondo; K Imada; F Kimura; T Ichinohe; Y Hashii; K Kato; Y Atsuta; S Taniguchi; T Fukuda
Journal:  Leukemia       Date:  2016-02-12       Impact factor: 11.528

2.  Predictive genetic testing of a bone marrow recipient-ethical issues involving unexpected results, gender issues, test accuracy, and implications for the donor.

Authors:  A Sexton; L Rawlings; M Jenkins; I Winship
Journal:  J Genet Couns       Date:  2013-08-30       Impact factor: 2.537

3.  First report of donor cell-derived acute leukemia as a complication of umbilical cord blood transplantation.

Authors:  Christopher J Fraser; Betsy A Hirsch; Vanessa Dayton; Michael H Creer; Joseph P Neglia; John E Wagner; K Scott Baker
Journal:  Blood       Date:  2005-08-23       Impact factor: 22.113

4.  Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.

Authors:  Nirali N Shah; Ulrike Bacher; Terry Fry; Katherine R Calvo; Maryalice Stetler-Stevenson; Diane C Arthur; Roger Kurlander; Kristin Baird; Barbara Wise; Sergio Giralt; Michael Bishop; Nancy M Hardy; Alan S Wayne
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

Review 5.  Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.

Authors:  Lacey Williams; Kimberley Doucette; Judith E Karp; Catherine Lai
Journal:  Bone Marrow Transplant       Date:  2021-03-08       Impact factor: 5.483

6.  Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee.

Authors:  R N Lown; J Philippe; W Navarro; S M van Walraven; L Philips-Johnson; M Fechter; R Pawson; M Bengtsson; M Beksac; S Field; H Yang; B E Shaw
Journal:  Bone Marrow Transplant       Date:  2014-04-07       Impact factor: 5.483

Review 7.  Risks and mechanisms of oncological disease following stem cell transplantation.

Authors:  Sergey V Anisimov; Asuka Morizane; Ana S Correia
Journal:  Stem Cell Rev Rep       Date:  2010-09       Impact factor: 5.739

8.  Lessons Learned from Donor Cell-Derived Myeloid Neoplasms: Report of Three Cases and Review of the Literature.

Authors:  Komal Galani Deshmukh; Katalin Kelemen
Journal:  Life (Basel)       Date:  2022-04-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.